Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 118 Publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NVjRfXdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTJUXI3UUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> M3TVZ|I2QTZyMkiy
KellyCis83 M2PsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTjTWM2OD1yLkG25qCKyrIkgJmwMlAzKM7:TR?= MojrNlU6PjB{OEK=
SK-N-AS MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\3VGlEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= NGKydogzPTl4MEK4Ni=>
SK-N-ASCis24 M2jJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2qzSmlEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= NVO2OlM1OjV7NkCyPFI>
U87 NVfWOFdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOwMVUxKM7:TR?= NFra[4M1QCCq M{[0WoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nlic3nsbYJqdmmw MUGyOVc2ODJ5Mx?=
HCT116 NVTLS3VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWwMlUuOi53IN88US=> NFPU[5M1QMLiaNMg NGfrdVZKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= NVWwS4dQOjV5NE[3OlM>
HT-29 NUjyT5B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nBPFAvPS1{LkWg{txO M4myO|Q5yqCqwrC= NHuyfHdKSzVyPUeuNuKhyrIEoEGuNFTDqM7:TR?= MXeyOVc1Pjd4Mx?=
Caco2 M4nXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[4dIdKOC53LUKuOUDPxE1? NYjrTmt3PDkEoHlCpC=> M3\nU2lEPTB;Nz6yOuKhyrIEoEGuOljDqM7:TR?= MkHhNlU4PDZ5NkO=
COLO 205 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqwOXUxNjVvMj61JO69VQ>? MYK0POKhcMLi M1LrfWlEPTB;MT62NeKhyrIEoECuNFLDqM7:TR?= NIDFUVQzPTd2Nke2Ny=>
SW480 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWwMlUuOi53IN88US=> MUS0POKhcMLi NUDkOphJUUN3ME20MlkzyqEEsdMgNE4{O8LizszN NX\vdY9VOjV5NE[3OlM>
HEK293T NXjjR4s2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEGwPIYyNTVizszN M4frXFQ5yqCqwrC= NID3[FFKSzVyPUKuOFLDqMLzwrCwMlA2yqEQvF2= MmXHNlU4PDZ5NkO=
Hep3B  M13u[mZ2dmO2aX;uJGF{e2G7 M1vDW|ExKM7:TR?= NHrGU2Y1QMLiaNMg Mne5doVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> MlK1NlU3OzN3NkS=
Hep3B  MoHzSpVv[3Srb36gRZN{[Xl? MW[wMlEuOTBizszN NXezemgzOjRiaB?= NX65UJhbe3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B M1fMbFI2PjN|NU[0
HEK293 M2r4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:5S4VrUUN3ME23MlE1yqEEsdMgNE4{PsLizszN MXiyOVYxOzF{Mh?=
DU145 MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnezTWM2OD1{LkK4xsDDucLiMD6wOOKh|ryP MWGyOVYxOzF{Mh?=
HCT15 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwOEJCpOKyyqByLkCxxsDPxE1? NYjzXo9nOjV4MEOxNlI>
T47D M{jsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q2XGlEPTB;Mz6xPOKhyrIEoECuNVHDqM7:TR?= M2\CflI2PjB|MUKy
SMMC-7721 MWLGeY5kfGmxbjDBd5NigQ>? MWi0NEDPxE1? NXPuWlBHPDhiaB?= MUfEUXNQ MWHpcoR2[2W|IN8zTFJCYCCob3PpJIZwem2jdHnvci=> M{DBOVI2PTR2M{[x
MDA-MB-231 NE\uPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG3NuKhcA>? MUTJR|UxRTJzLkNCpOKyyqB2LkNCpO69VQ>? M2HhSFI2PDh4MkG5
MCF-7 NYr4UI5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n6XFczyqCq NFn5bHdKSzVyPUGwMlnDqMLzwrCyMlHDqM7:TR?= MoO2NlU1QDZ{MUm=
Jurkat NVm0W2dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXZO|LDqGh? NV\Rcmh5UUN3ME2xMlLDqMLzwrCxMlXDqM7:TR?= M13JXVI2PDh4MkG5
HeLa MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV23NuKhcA>? M3m0TWlEPTB;Mz65xsDDucLiMj6zxsDPxE1? MlXnNlU1QDZ{MUm=
MCF7  NFz0dlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVW1MVExOCEQvF2= M2Ltdlch\A>? M{Tab4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYr4[HRWOjV2N{K2NVk>
K562 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:2TmY4OsLiaB?= M33SVGlEPTB;MD6yPeKh|ryP MUOyOVI5OjZ3Mx?=
K/VP.5 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzw[45mPzMEoHi= NVvabVY1UUN3ME20MlnDqM7:TR?= M4LqN|I2Ojh{NkWz
SH-EP  MWDGeY5kfGmxbjDBd5NigQ>? Moe4NlDDqM7:Zz;tcC=> NHHpT|gzPMLiaB?= NWLQd5ZVcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGWwZH;n[Y5wfXNiRFXQVC=> NXvjTZFMOjV{NkG5PFE>
SCC25 NUC0V4VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIraT|AzPMLiaB?= M{jEfWlEPTB;NEOuN:KhyrIEoEGuNVLDqM7:TR?= MV[yOVIzODd{OR?=
CAL27 NX3rdFA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[yOOKhcA>? M1zLe2lEPTB;NUKuNeKhyrIEoEGuNFnDqM7:TR?= Mlv6NlUzOjB5Mkm=
FaDu M3zM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHJNlTDqGh? NEfodXRKSzVyPUK1Mlg6yqEEsdMgNU4yO8LizszN MX[yOVIzODd{OR?=
SCC25 NX;wNWRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK0POKhcA>? NX\aSmlKUUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> M37YR|I2OjJyN{K5
CAL27 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXVNo01QMLiaB?= MYLJR|UxRTF6LkK0xsDDucLiMT6xOeKh|ryP NI[2fYczPTJ{MEeyPS=>
FaDu MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjidmZTPDkEoHi= M{\jUWlEPTB;Nj60N:KhyrIEoEGuNVPDqM7:TR?= MnfDNlUzOjB5Mkm=
SCC25 NXfo[VVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDMO|LDqGh? NWXs[2RnUUN3ME24MlQyyqEEsdMgNU4yOcLizszN NVrKTpU1OjV{MkC3Nlk>
CAL27 NUTTWXQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlKyO|LDqGh? MVPJR|UxRTRwMkhCpOKyyqBzLkG0xsDPxE1? NVj2Z2R6OjV{MkC3Nlk>
FaDu MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnOO|LDqGh? M1fCTGlEPTB;NT6wNuKhyrIEoEGuNVXDqM7:TR?= MY[yOVIzODd{OR?=
MCF-7 M2f0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXtOFjDqGkEoB?= NFnBVJlFVVOR M{fSe2lEPTB;Nz6yxsDDucLiMD64xsDPxE1? MWKyOVIyPjN5OB?=
T-47D NXzTRlJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M122VVQ5yqCqwrC= NVu0NFIyTE2VTx?= M1r5TGlEPTB;Nz63xsDDucLiMD63xsDPxE1? M3r1PFI2OjF4M{e4
MDA-MB-231 NEe0dG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTZOFjDqGkEoB?= MX;EUXNQ MWDJR|UxRTF{LklCpOKyyqBzLkFCpO69VQ>? MVKyOVIyPjN5OB?=
DU145 MVfBdI9xfG:|aYOgRZN{[Xl? NFr3OFgyOC1zMECg{txO NIXRSnk5KGh? M{GwUGROW09? NHjkemtqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= NFTQWVQzPTF2OU[4NS=>
DU145 stem-like NXu2d41sSXCxcITvd4l{KEG|c3H5 NV3BOXNJOTBvMUCwJO69VQ>? NELRNZY5KGh? MoPFSG1UVw>? Mkj2bY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NW\VVYVyOjVzNEm2PFE>
DU145 M3r6fWZ2dmO2aX;uJGF{e2G7 MU[xNE0yODBizszN MlvLNkBp NFjNO5RFVVOR MXrpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M2XDNVI2OTR7Nkix
DU145 stem-like MkHSSpVv[3Srb36gRZN{[Xl? NW\kU5ByOTBvMUCwJO69VQ>? NFXXXoczKGh? Mo[xSG1UVw>? NEDqN5pqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXiyOVE1QTZ6MR?=
UW228-3 MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\QRnAxNjBzLUOwNEDPxE1? NHfmNYU1QCCq NVHHXI9YTE2VTx?= M2\Ze2lEPTB;MD65PeKh|ryP MU[yOVEyQTF6NR?=
NSCs MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\oT|AvODFvM{CwJO69VQ>? MUW0PEBp NEjxcldFVVOR Ml7ZTWM2OD1yLkOtN:Kh|ryP MnTINlUyOTlzOEW=
MKL-1  M1z1emZ2dmO2aX;uJGF{e2G7 NW\iOFRLOTBvMUCwNEBvVQ>? NX3WNHBHPCCm NI[z[pZqdmS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gUWhENUliZYjwdoV{e2mxbh?= MX[yOVEyPjd3NB?=
MCF7 EV MlHySpVv[3Srb36gRZN{[Xl? MWSxNE0yODBizszN NH:yVIMz6oDLaB?= NH;CbGdqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? MWKyOVA5QDJyMx?=
MCF 7BMI1 NGXVZnZHfW6ldHnvckBCe3OjeR?= NV\XNGFlOTBvMUCwJO69VQ>? NY[0SndCOuLCiXi= MkLXbY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> NEDVbo8zPTB6OEKwNy=>
MCF7 EV NHq4OXZHfW6ldHnvckBCe3OjeR?= NFnFNlgyOC1zMECg{txO MnrFNwKBkWh? MmrTSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u NVu5fIpKOjVyOEiyNFM>
MCF7 BMI1 M3GzN2Z2dmO2aX;uJGF{e2G7 MYOxNE0yODBizszN NVjYNVhxOuLCiXi= NVvlN|BRTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v NV\We3RROjVyOEiyNFM>
HepG2 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXHSG84TE2VT9Mg NVu1d5dRUUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> Mo\rNlUxPzh|MUG=
MOLT-3 NVrXRnpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPYSG1UV8Li NX\PUoFEUUN3ME2wMlA2OcLiwsJCpFAvODB{wrFOwG0> MYiyOVA4QDNzMR?=
HT1080 NInRd41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:xMVExOCEQvF2= NUfWZYhlPC9{ND:0PEBp MWDEUXNQyqB? M4XRTYlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= M4rT[|I2ODd6ME[0
HT1080 NU\DSZE{TnWwY4Tpc44hSXO|YYm= MlqzNE4xODBzLUGwNEDPxE1? MYCxMVI1KGh? M4\lNWROW00EoB?= M4WxdIlv\HWlZYOgdE1xPTNqc3XyNVUqKGmwIHLveIghfGmvZT2gZY5lKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= MUiyOVA4QDB4NB?=
HT1080 M1TEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm4NW13OC5yMECxMVExOCEQvF2= NYX1ZlQ1OjRiaB?= NYXKXpZqTE2VT9Mg MWfjZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| NGTCcXYzPTB5OEC2OC=>
HD-MY-Z MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof6NlQwPDhxN{KgbC=> NXvBfnByUUN3MP-8olExOCEQvF2= MVSyOVA1QDJ|Nh?=
DOHH-2 M2q5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[yOEBp MWLJR|Ux97zgMUCwJO69VQ>? MlXVNlUxPDh{M{[=
DOHH-2 MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj2PFZSPDhiaB?= NILvRY1KSzVyPUG5MlnDqM7:TR?= MYSyOVA1QDJ|Nh?=
DOHH-2 M4P3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYW3NkBp NVz6OoRtUUN3ME21xsDPxE1? NXHj[VZxOjVyNEiyN|Y>
REH MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL1UIRuOjRiaB?= M1u2VGlEPTB;MD6wNlfDqM7:TR?= MnrPNlUxPDh{M{[=
REH MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPjR3hkPDhiaB?= Mn7yTWM2OD1yLkCxOOKh|ryP MnLnNlUxPDh{M{[=
REH Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvMTIRzPzJiaB?= NEjRWFJKSzVyPUCuNFE2yqEQvF2= MX[yOVA1QDJ|Nh?=
HH NFnIcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO3NpYzPCCq MoT1TWM2OD1zMESuO:Kh|ryP MmHJNlUxPDh{M{[=
HH MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWe0PEBp M33MeGlEPTB;NEiuOuKh|ryP M1foWFI2ODR6MkO2
HH NV7yU|RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7jTo04OiCq NHfnS4RKSzVyPUG0MlfDqM7:TR?= NWK5SYk3OjVyNEiyN|Y>
HuT-78 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWyOEBp M4X0dmlEPTB;OT6zxsDPxE1? M4XofFI2ODR6MkO2
HuT-78 NXTDVYU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfCc2I1QCCq NH[zOnBKSzVyPUSuN:Kh|ryP NY\oT|A{OjVyNEiyN|Y>
HuT-78 M4\GUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\JOmIzPzJiaB?= NVz4PYJrUUN3ME20MlLDqM7:TR?= M4rvNVI2ODR6MkO2
OPM-2 MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSyOEBp MlTkTWM2OD1{ND6xxsDPxE1? M1zGd|I2ODR6MkO2
OPM-2 MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPtT5d4PDhiaB?= MnvxTWM2OD12wrFOwG0> MWmyOVA1QDJ|Nh?=
OPM-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\PO|IhcA>? Mne1TWM2OD1zLkRCpO69VQ>? NFP5blMzPTB2OEKzOi=>
RPMI-8226 NWrLXZJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH21NVczPCCq M4H3bWlEPTB;MUC2MlbDqM7:TR?= NX;SO4VmOjVyNEiyN|Y>
RPMI-8226 NX;KeoVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HEWVQ5KGh? M2jTR2lEPTB;OUGuNeKh|ryP MnnuNlUxPDh{M{[=
RPMI-8226 NFq4co1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;SUVczKGh? NH3LU5VKSzVyPUG0MlnDqM7:TR?= NY\D[4VWOjVyNEiyN|Y>
U-266 NIfBbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLwNlQhcA>? M3TVVWlEPTB;OE[uNuKh|ryP M4HUUVI2ODR6MkO2
U-266 Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfyOFghcA>? NFmzVHZKSzVyPU[4MlTDqM7:TR?= M3H2TlI2ODR6MkO2
U-266 NFq2SmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWOzU5hbPzJiaB?= NUe2U4pNUUN3ME2yO{41yqEQvF2= NFnEXlEzPTB2OEKzOi=>
Kelly MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rCZVAuOTBizszN M4e3RlczyqCq NVPjOVNqUUN3ME2xMlUyQMLizszN MVuyOVAxQDlyMB?=
SH-SY5Y  NWT5VplwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[wMVExKM7:TR?= MlTwO|LDqGh? MXHJR|UxRTBwN{W0xsDPxE4EoB?= Mlz3NlUxODh7MEC=
SK-N-AS NGDvbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzUNE0yOCEQvF2= NFfTZ3g4OsLiaB?= NEfjdlBKSzVyPUGuO|EzyqEQvF5CpC=> MlTsNlUxODh7MEC=
SK-N-DZ MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\tZVAuOTBizszN M{LkcVczyqCq NIXqVlVKSzVyPUWuOFg2yqEQvF2= NF3OXHgzPTByOEmwNC=>
HepG2 NHLhTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3YXHZWPDkEoHi= M1LOS2ROW00EoB?= MojTTWM2OD1zMz62OeKhyrIEoECuPVLDqM7:TR?= NE\qeIEzPDl7NkGzOi=>
A549 NXXMTplGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XHNFQ5yqCq MkPlSG1UV8Li MVTJR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= MmK1NlQ6QTZzM{[=
MCF7 MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX60POKhcA>? MY\EUXNQyqB? M1vOeGlEPTB;OEGuNFnDqMLzwrCxOE4zOcLizszN NGHy[I0zPDl7NkGzOi=>
HL-60  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\Xfo84OsLiaB?= M4[4N2lEPTB;MD6xNwKBjc7:TR?= Mmj3NlQ6QTNyMUS=
HL-60[R] NGTFOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUi3NuKhcA>? M361W2lEPTB;Mz6xNwKBjc7:TR?= MV:yOFk6OzBzNB?=
MIAPACA M3KzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfTS2k2OD1zLkOgxtEhOC5yMzFOwG0> MXiyOFk2Ozh{MR?=
MCF-7 NV\0ZpJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvRS2k2OD1yLkK1JOKyKDBwMTFOwG0> MY[yOFk2Ozh{MR?=
HeLa NVfsfIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILqVHZIUTVyPUCuOlQhyrFiMD60JO69VQ>? NEXqW3ozPDl3M{iyNS=>
MO59K  NIPDSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HRSFch\A>? NXTwWFk2UUN3ME2wMlE46oDHzszN NWi4VHY1OjR7NUO1OlE>
MO59J NHrmXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnsfIY4KGR? NXzPRohTUUN3ME2wMlHjiIYQvF2= MWGyOFk2OzV4MR?=
ME 180 NUixdIE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;Tb5FlPDkEoHlCpC=> NYLLXHFVUUN3ME24MlnDqMLzwrCwMlPjiIYQvF2= M1:zeVI1QTV|MEK3
MCF-7 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jm[lQ5yqCqwrC= M2rySWlEPTB;MkOuPUDDuSByLkRihKXPxE1? MViyOFk2OzB{Nx?=
HeLa M2DkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD0bJQ1QMLiaNMg NIrkUpJKSzVyPUSuO|EhyrFiMT605qCG|ryP NYi5c|RmOjR7NUOwNlc>
MDA-MB-453 M3ntNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T2SFQ5yqCqwrC= M{DIbWlEPTB;MUKuOUDDuSByLki15qCG|ryP M3fmeVI1QTV|MEK3
MDA-MB-231 NYjSW|dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[0POKhcMLi M3jRWmlEPTB;MkSuNlIhyrFiMj65OQKBjc7:TR?= NFXacXYzPDl3M{CyOy=>
PC-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXq0POKhcMLi MVrJR|UxRTF2LkSgxtEhOy5{M,MAie69VQ>? NY\pVJB{OjR7NUOwNlc>
HT-29 NVPkR|dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[xZWRuPDkEoHlCpC=> M3nzTGlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= M{S1N|I1QTV|MEK3
BGC-823 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zzeFQ5yqCqwrC= NFTqUW9KSzVyPUSzMlc1KMLzIEWuNVPjiIYQvF2= M2KwVVI1Pzl|OEe3
HeLa M1HOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzpPFM1QMLiaNMg MUfJR|UxRTJyOT65NEDDuSBzMz60NkDjiIYQvF2= Mle3NlQ4QTN6N{e=
A549 NF7rNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jjS|Q5yqCqwrC= M2rPWWlEPTB;MUO5MlU1KMLzIEeuNFXjiIYQvF2= NWXUeFQ6OjR5OUO4O|c>
HK-2 MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jmXFQ5yqCqwrC= MlXQTWM2OD17LkG3JOKyKDFwNUlihKXPxE1? MWCyOFc6Ozh5Nx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
- Collapse

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
- Collapse
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03264131 Recruiting Drug: Brentuximab Vedotin|Drug: CHEP Lymphoma|Adult T-Cell Leukemia/Lymphoma|Lymphatic Diseases UNC Lineberger Comprehensive Cancer Center|Seattle Genetics Inc. October 15 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID